ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
Employee Vinayak Sawant sold 1,100 shares of Rubicon Research Ltd worth ₹0.20 Crore. This disclosure is a routine regulatory filing under PIT regulations.
Rubicon Research reported a strong Q1 FY27 with revenue growing 51% YoY to ₹534 Cr and PAT surging over 95% to ₹85 Cr.
Rubicon Research delivers stellar Q1FY27 results with a 51% revenue jump and 100%+ PAT growth, largely fueled by strong US specialty sales and successful inorganic integration.
Rubicon Research reported stellar Q1FY27 results with 51.6% YoY revenue growth. Management revised Operating EBITDA margin guidance upwards to at least 23% for FY27.
Rubicon Research Ltd reported revenue from operations of ₹534.3 Cr (+51.6% YoY) and net profit of ₹84.8 Cr (+95.8% YoY) for Q1 FY27.
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.
Rubicon Research delivered a strong Q4 FY26 with 44% revenue growth and 112% profit increase, driven by a robust product pipeline and stable pricing despite outsourcing manufacturing for excess demand.
Rubicon Research (Q4 FY26) reported revenue of ₹5,139M (up 43.5% YoY) and PAT of ₹768M (up 111.8% YoY). Strategy focuses on specialty products and US nasal spray market leadership.
Rubicon Research Ltd reported revenue from operations of ₹513.9 Cr (+43.5% YoY) and net profit of ₹76.8 Cr (+112.2% YoY) for Q4 FY26.